Canada Markets close in 4 hrs 42 mins

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.08-0.08 (-1.61%)
As of 11:11AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close5.16
Open5.11
Bid5.06 x 1100
Ask5.12 x 1300
Day's Range4.93 - 5.13
52 Week Range0.16 - 5.90
Volume50,772
Avg. Volume1,142,419
Market Cap621.562M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.00
  • GlobeNewswire

    Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

    – Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended Jun

  • Zacks

    CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Aeterna Zentaris Announces Effective Date of Share Consolidation

    TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidati